XML 25 R9.htm IDEA: XBRL DOCUMENT
v3.20.4

Acquisitions | 3 Months Ended
--- | ---
Jan. 31, 2021
Business Combination And Asset Acquisition [Abstract] |
Acquisitions | Acquisitions The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during the three months ended January 31, 2021 and fiscal 2020:
(In millions) | January 31, 2021 |  | October 31, 2020
Technology | $ | 72.0 |  |  | $ | — |
In-Process Research & Development (IPR&D) | 20.0 |  |  | — |
Customer relationships | 6.7 |  |  | 11.4 |
Trademarks | 0.8 |  |  | 5.1 |
Other | — |  |  | 3.9 |
Total identifiable intangible assets | $ | 99.5 |  |  | $ | 20.4 |
Goodwill | 49.6 |  |  | 15.3 |
Net tangible assets | (21.8) |  |  | (0.3) |
Fair value of contingent consideration | (37.9) |  |  | — |
Total closing purchase price | $ | 89.4 |  |  | $ | 35.4 |
All acquisitions were funded by cash generated from operations or facility borrowings. For business acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For asset acquisitions, the Company recorded tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition. The Company believes these acquisitions strengthen CooperSurgical's and CooperVision’s businesses through the addition of new distributors or complementary products and services. Fiscal Year 2021 On January 19, 2021, CooperVision acquired all of the remaining equity interests of a privately-held medical device company that develops spectacle lenses for myopia management. The fair value remeasurement of our previous equity investment immediately before the acquisition resulted in a gain of $11.5 million, which was recorded in other income. The terms of the acquisition include upfront cash consideration paid at closing of approximately $40.9 million attributable to the equity interests not held by the Company on the closing date. The transaction also includes potential payments of future consideration that are contingent upon the achievement of the regulatory approval milestone (the regulatory approval payment) and the acquired business reaching certain revenue thresholds over a specified period (the revenue pa yments). The undiscounted range of the contingent consideration is zero to $139.1 million payable to the other former equity interest owners. The purchase price allocation is preliminary, and we are in the process of finalizing information primarily related to taxes and the corresponding impact on goodwill. The estimated fair value of the contingent consideration on the acquisition date was approximately $37.9 million, and, accordingly, the Company recorded a liability of approximately $30.2 million, which represents the fair value of the contingent consideration payable to the other former equity interest owners. The fair value of the regulatory approval payment was determined using an option pricing framework based on the expected payment under the contractual terms and the estimates of the probability of achieving the regulatory approval. The fair value of the revenue payments was determined using a Monte Carlo simulation based on the revenue projections and the expected payment for each simulation. The fair value of the contingent consideration will be remeasured at each subsequent reporting period, and the change in fair value will be recognized in the Consolidated Statements of Income and Comprehensive Income. On December 31, 2020, CooperSurgical completed the acquisition of a privately-held in vitro fertilization (IVF) cryo-storage software solutions company. The purchase price allocation is preliminary and we are in the process of finalizing information and the corresponding impact on goodwill. The pro forma results of operations of these acquisitions have not been presented because the effect of the business combinations described above was not material to the consolidated results of operations. Fiscal Year 2020 On December 13, 2019, CooperSurgical completed the acquisition of a privately-held distributor of IVF medical devices and systems. On August 7, 2020, CooperVision completed the acquisition of a privately-held U.S contact lens manufacturer focusing on ortho-k lenses. This acquisition expands CooperVision’s specialty eye care portfolio and its leadership in addressing the increasing severity and prevalence of myopia. The purchase price allocation is preliminary and the Company is in the process of finalizing information and the corresponding impact on goodwill. The pro forma results of operations of these acquisitions have not been presented because the effect of the business combination described above was not material to the consolidated results of operations.

X
- Definition Business Combination And Asset Acquisition [Abstract] + References No definition available. + Details
Name: | coo_BusinessCombinationAndAssetAcquisitionAbstract
Namespace Prefix: | coo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination And Asset Acquisition [Text Block] + References No definition available. + Details
Name: | coo_BusinessCombinationAndAssetAcquisitionTextBlock
Namespace Prefix: | coo_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration